1. Pink Sheet
  2. >>Geography

CorMedix Launches Catheter Lock Product In Germany, Looks Ahead To U.S.

The company is shipping Neutrolin, a device containing an antimicrobial/antifungal agent and two anti-clotting agents, in Germany to “lock” catheters between dialysis sessions and prevent blood stream infections and clots. The New Jersey firm also is working with FDA to get the product approved in the U.S. as a specialty pharmaceutical.

It’s been a long time getting to market for CorMedix Inc.’s Neutrolin since the company licensed the product in 2008, but the product, which can prevent blood stream infections and clots in central venous catheter-using patients, is being shipped to dialysis centers in Germany now. CorMedix is also in discussions with FDA about a regulatory path forward for Neutrolin as a specialty pharmaceutical product in the U.S.

Bridgewater, N.J.-based CorMedix obtained worldwide development, manufacturing and marketing rights to Neutrolin from ND Partners LLC in February 2008 when the company was still privately owned [See Deal]

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Germany

More from Europe

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds

 
• By Cathy Kelly

Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.

Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry

 
• By Leela Barham

Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.